Business & Industry
Incyte Expands Haematology Portfolio with Vega Acquisition
Incyte has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction valued at up to $2bn, reinforcing its presence in haematology with the addition of a late-stage treatment candidate for bleeding disorders. Under the terms...
Business & Industry
GSK Targets Nuvalent in $10.6 Billion Oncology Acquisition
GSK has agreed to acquire Nuvalent in a transaction valued at $10.6 billion, positioning the UK-based pharmaceutical company for its largest acquisition in more than a decade and adding two late-stage lung cancer treatments to its portfolio. Through a...
Business & Industry
Firefly Bio Acquisition Strengthens J&J Cancer Pipeline
Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology....
BioPharma
Daewoong and Chime Biologics Partner for Biosimilar Push
Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics...
Business & Industry
SK Biopharmaceuticals Opens LinX Hub for Korean Biotech
SK Biopharmaceuticals has established a new innovation platform in the United States aimed at helping Korean biotechnology and pharmaceutical companies expand their presence in international markets. The company announced Monday that it officially opened SK Life Science LinX at...
BioPharma
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position
GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8...
Business & Industry
Sanofi and Owkin Partner to Co-Develop Agentic AI Tools for Drug Discovery
Sanofi has entered into a multi-year agreement with France-based agentic AI company Owkin to jointly develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin's K Pro platform, an advanced AI system designed to augment drug...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read